The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review

. 2014 Sep; 12(5): 444–461.
Published online 2014 Sep. doi:  10.2174/1570159X12666140619204251

At least 10-20% of the patients suffering from depression meet criteria for treatment-resistant depression (TRD)…

Most studies demonstrated that the NMDA antagonist ketamine has rapid antidepressant effects in TRD patients, confirming the active role of glutamate in the pathophysiology of this complex condition. Ketamine has been demonstrated to be rapidly effective and was associated with a significant clinical improvement in depressive symptoms within hours after administration. Also, ketamine was also found to be effective in reducing suicidality in TRD samples.

Treatment-resistant depression (TRD) affects more than 1% of individuals in the United States, and approximately 30% of all depressed patients may be classified as affected by refractory depression

Read More

Ready to Live Life Again?

If you are currently suffering from suicidal thoughts, please contact your local crisis center or call 911.

Schedule your Free Consultation